C5's Life Sciences and Chemical Series:
Rules, Risk and Readiness in Europe

The life sciences and chemical industries in Europe are in the midst of a perfect storm of regulatory change, *culminating with the European Commission's announcement in July 2025 of its new strategy for life sciences:* ***"Choose Europe for life sciences — A strategy to position the EU as the world's most attractive place for life sciences by 2030,"*** and exemplified by the following:

- **The EU Pharma Reform Package**, now in the trilogue stage, with anticipated adoption by 2026 would mark the most significant revision to the EU's pharmaceutical laws in a generation.
- **The REACH PFAS Restriction Proposal** which after a review of extensive comments from the 2023 consultation period is moving through ECHA's RAC and SEAC committees, with a second public consultation on SEAC's draft opinion anticipated in 2026.
- **The EU AI Act** – the world's first law governing AI- is in force with obligations through 2026–2027 and having profound significance for the life sciences.
- **The EU HTA Act** now, one year in effect, calls for the creation of a single health technology assessment for all EU member states, i.e., joint clinical assessments for all new medicines and therapies requiring a marketing authorization, and will have tremendous impact on market access throughout Europe
- **The UPC**, now its second year has had profound impact on European patent law, with particular significance to life sciences patents.
- **The New EU Product Liability Directive (PDL)** significantly changes the EU's product liability laws posing a new threat to the life sciences and chemical sectors and also has significant implications for AI technologies.
- **The European Biotech Act** initiative is currently in preparation.

To help you navigate your way through this tempest, C5 is pleased to offer the following European series of life sciences events *(see other side of page)* delivering end-to-end coverage, from AI, data and PLD liability, to UPC patent strategy, PFAS compliance, and HTA/market access. Whether you sit in legal, regulatory, compliance, IP, safety, market access, or the C-suite, you can't afford to miss this series of events.

PARTNERSHIP OPPORTUNITIES

Partner with C5's Life Sciences Europe 2026 events on your terms. Align with the full series or select one or more conferences that match your goals. As a sponsor, your organization is positioned in front of senior legal, regulatory, compliance, IP, safety, and market-access decision-makers across biopharma, MedTech, and digital health. Whether your focus is AI governance, product liability/ collective redress, UPC patent strategy, PFAS/EHS, or HTA/market access, we'll tailor speaking, networking, and branding formats to showcase your expertise.

Get in touch to discuss single-event, multi-event, or series-level packages. Get in touch to discuss bespoke partnership opportunities.

Aaron Goldstein
Senior Business Development Manager
C5
Phone: **+1 212-352-3220 Ext. 5512**
Email: **A.Goldstein@C5-Online.com**

C5-Online.com/Life-Sciences
SCAN TO VISIT WEBSITE

C5's 2026 Life Sciences and Chemical Series:

March 2026, Brussels

A summit that celebrates women leaders in life sciences law throughout Europe, while also welcoming men to participate, providing invaluable opportunities for networking and collaboration. Participants have the opportunity to connect, engage, and learn from inspiring attorneys and executives in the biotech, pharmaceutical, and medical device sectors, and stay informed on the latest developments and challenges facing the industry.

Who it's for: GCs, VPs/Heads of Legal, IP Compliance, and counsel from life sciences companies as well as law firm attorneys practicing in the life sciences sectors.

SCAN TO VISIT WEBSITE

April 2026, Brussels

What it covers: End-to-end EU AI Act readiness for R&D, clinical, pharmacovigilance, quality, and commercial use cases; MDR/IVDR intersection; governance for LLMs and SaMD; and liability exposure under the new PLD.

Who it's for: In-house counsel, regulatory/quality leaders, AI/ML and data officers, privacy & security heads, law-firm partners, and external advisors aligning products and processes to EU timelines.

SCAN TO VISIT WEBSITE

May 2026, Brussels

What it covers: The status and scope of the EU-wide PFAS restriction, essential-use and exemptions, supply-chain mapping, remediation, and litigation/insurance implications for life-sciences manufacturing and devices.

Who it's for: EHS and regulatory leads, in-house environmental counsel, outside counsel, and operations executives responsible for materials and compliance.

SCAN TO VISIT WEBSITE

May 2026, Amsterdam

What it covers: UPC strategies (PI practice, jurisdiction, remedies), SPCs, originator/innovator v. biosimilar/generic battles, and damages/settlement dynamics.

Who it's for: IP litigators, patent counsel, European litigation strategists, outside counsel, and litigation funders monitoring UPC action.

SCAN TO VISIT WEBSITE

June 2026, Brussels

What it covers: EU product-liability, class action, and mass-harm trends post-PLD, safety/vigilance & recalls, labeling and promotion disputes, and coordination across Member State procedures.

Who it's for: Product-liability counsel, litigation & risk leaders, insurers, claims managers, and external defense counsel aligning EU and global strategies.

June 2026, Brussels

What it covers: HTA Regulation operations, 2026–2027 JCA roadmaps, national pricing & reimbursement, managed-entry agreements, and evidence strategies that shorten time-to-access across fragmented systems, plus touchpoints with the evolving pharma package and biotech initiative.

Who it's for: Market access and HEOR leaders, regulatory & legal counsel, government affairs, pricing/reimbursement teams, and clinical evidence strategists.

C5-Online.com/Life-Sciences
SCAN TO VISIT WEBSITE